PPARα ligands and clinical trials:: cardiovascular risk reduction with fibrates

被引：16

作者：

Robins, SJ ^{[1
]}

机构：

[1] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA

来源：

JOURNAL OF CARDIOVASCULAR RISK | 2001年 / 8卷 / 04期

关键词：

cholesterol; clinical trials; coronary heart disease; diabetes; fibrates; HDL cholesterol; insulin resistance; lipids; PPARs;

D O I：

10.1097/00043798-200108000-00003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：195 / 201

页数：7

共 28 条

[1]

[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360

[2]

[Anonymous], 1971, Br Med J

[3]

[Anonymous], BR MED J

[4]

CARLSON LA, 1988, ACTA MED SCAND, V223, P405

[5] Hyperinsulinemia as an independent risk factor for ischemic heart disease [J].

Despres, JP ;

Lamarche, B ;

Mauriege, P ;

Cantin, B ;

Dagenais, GR ;

Moorjani, S ;

Lupien, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (15) :952-957

[6] Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients [J].

Ericsson, CG ;

Hamsten, A ;

Nilsson, J ;

Grip, L ;

Svane, B ;

deFaire, U .

LANCET, 1996, 347 (9005) :849-853

[7] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].

FRICK, MH ;

ELO, O ;

HAAPA, K ;

HEINONEN, OP ;

HEINSALMI, P ;

HELO, P ;

HUTTUNEN, JK ;

KAITANIEMI, P ;

KOSKINEN, P ;

MANNINEN, V ;

MAENPAA, H ;

MALKONEN, M ;

MANTTARI, M ;

NOROLA, S ;

PASTERNACK, A ;

PIKKARAINEN, J ;

ROMO, M ;

SJOBLOM, T ;

NIKKILA, EA .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245

[8] LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN-A-I AND APOLIPOPROTEIN-B AND LIPOPROTEIN-(A) ABNORMALITIES IN MEN WITH PREMATURE CORONARY-ARTERY DISEASE [J].

GENEST, J ;

MCNAMARA, JR ;

ORDOVAS, JM ;

JENNER, JL ;

SILBERMAN, SR ;

ANDERSON, KM ;

WILSON, PWF ;

SALEM, DN ;

SCHAEFER, EJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (04) :792-802

[9] RATIONALE AND DESIGN OF A SECONDARY PREVENTION TRIAL OF INCREASING SERUM HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND REDUCING TRIGLYCERIDES IN PATIENTS WITH CLINICALLY MANIFEST ATHEROSCLEROTIC HEART-DISEASE (THE BEZAFIBRATE INFARCTION PREVENTION TRIAL) [J].

GOLDBOURT, U ;

BEHAR, S ;

REICHERREISS, H ;

AGMON, J ;

KAPLINSKY, E ;

GRAFF, E ;

KISHON, Y ;

CASPI, A ;

WEISBORT, J ;

MANDELZWEIG, L ;

ABINADER, E ;

AHARON, L ;

BRAUN, S ;

DAVID, D ;

FLICH, M ;

FRIEDMAN, Y ;

KRISTAL, N ;

LEIL, N ;

MARKIEWICZ, W ;

MARMOR, A ;

PALANT, A ;

PELLED, B ;

RABINOWITZ, B ;

REISIN, L ;

ROGUIN, N ;

ROSENFELD, T ;

SCHLESINGER, Z ;

SCLAROVSKY, S ;

SHERF, L ;

TZIVONI, D ;

ZAHAVI, I ;

ZION, M ;

BRUNNER, D ;

FRIDENSOHN, A ;

JAFARI, J ;

OSTFELD, B ;

ROCHFLEISH, S ;

SCHNEIDER, H ;

KHALID, S ;

NARINSKY, R ;

ROTZAK, R ;

VITRAI, J ;

PELLED, B ;

PARDU, J ;

LANIADO, S ;

ESHCHAR, Y ;

ARDITI, A ;

BOTWIN, S ;

ROGUIN, N ;

YAHALOM, M .

AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (11) :909-915

[10] Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects -: Implications for preventing coronary heart disease during the prediabetic state [J].

Haffner, SM ;

Mykkänen, L ;

Festa, A ;

Burke, JP ;

Stern, MP .

CIRCULATION, 2000, 101 (09) :975-980

← 1 2 3 →